{
  "drugid": "RxNorm:121243",
  "drugname": "voriconazole",
  "guidelinename": "CYP2C19 and Voriconazole",
  "url": "https://cpicpgx.org/guidelines/guideline-for-voriconazole-and-cyp2c19/",
  "guidelinepharmgkbids": [
    "PA166161537"
  ],
  "citations": [
    {
      "pmid": "27981572",
      "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC®) Guideline for CYP2C19 and Voriconazole Therapy",
      "authors": [
        "Moriyama Brad",
        "Obeng Aniwaa Owusu",
        "Barbarino Julia",
        "Penzak Scott R",
        "Henning Stacey A",
        "Scott Stuart A",
        "Agúndez José A G",
        "Wingard John R",
        "McLeod Howard L",
        "Klein Teri E",
        "Cross Shane",
        "Caudle Kelly E",
        "Walsh Thomas J"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2016
    }
  ],
  "recommendations": [
    {
      "implications": {
        "CYP2C19": "n/a"
      },
      "drugrecommendation": "No recommendation",
      "classification": "No Recommendation",
      "phenotypes": {
        "CYP2C19": "Indeterminate"
      },
      "activityscore": {},
      "allelestatus": {},
      "lookupkey": {
        "CYP2C19": "Indeterminate"
      },
      "comments": "n/a",
      "population": "pediatrics",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C19": "n/a"
      },
      "drugrecommendation": "No recommendation",
      "classification": "No Recommendation",
      "phenotypes": {
        "CYP2C19": "Indeterminate"
      },
      "activityscore": {},
      "allelestatus": {},
      "lookupkey": {
        "CYP2C19": "Indeterminate"
      },
      "comments": "n/a",
      "population": "adults",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C19": "Higher dose-adjusted trough concentrations of voriconazole compared with normal metabolizers"
      },
      "drugrecommendation": "Initiate therapy with recommended standard of care dosing",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2C19": "Intermediate Metabolizer"
      },
      "activityscore": {},
      "allelestatus": {},
      "lookupkey": {
        "CYP2C19": "Intermediate Metabolizer"
      },
      "comments": "Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring, and comorbidities.",
      "population": "adults",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C19": "Higher dose-adjusted trough concentrations of voriconazole compared with normal metabolizers"
      },
      "drugrecommendation": "Initiate therapy with recommended standard of care dosing",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2C19": "Intermediate Metabolizer"
      },
      "activityscore": {},
      "allelestatus": {},
      "lookupkey": {
        "CYP2C19": "Intermediate Metabolizer"
      },
      "comments": "Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring, and comorbidities.",
      "population": "pediatrics",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C19": "Higher dose-adjusted trough concentrations of voriconazole compared with normal metabolizers"
      },
      "drugrecommendation": "Initiate therapy with recommended standard of care dosing",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "activityscore": {},
      "allelestatus": {},
      "lookupkey": {
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "comments": "Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring, and comorbidities.",
      "population": "adults",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C19": "Higher dose-adjusted trough concentrations of voriconazole compared with normal metabolizers"
      },
      "drugrecommendation": "Initiate therapy with recommended standard of care dosing",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "activityscore": {},
      "allelestatus": {},
      "lookupkey": {
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "comments": "Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring, and comorbidities.",
      "population": "pediatrics",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C19": "Higher dose-adjusted trough concentrations of voriconazole and may increase probability of adverse events"
      },
      "drugrecommendation": "Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole. In the event that voriconazole is considered to be the most appropriate agent, based on clinical advice, for a patient with poor metabolizer genotype, voriconazole should be administered at a preferably lower than standard dosage with careful therapeutic drug monitoring.",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "activityscore": {},
      "allelestatus": {},
      "lookupkey": {
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "comments": "Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring, and comorbidities.",
      "population": "adults",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C19": "Higher dose-adjusted trough concentrations of voriconazole and may increase probability of adverse events"
      },
      "drugrecommendation": "Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include liposomal amphotericin B and posaconazole. In the event that voriconazole is considered to be the most appropriate agent, based on clinical advice, for a patient with poor metabolizer genotype, voriconazole should be administered at a preferably lower than standard dosage with careful therapeutic drug monitoring.",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "activityscore": {},
      "allelestatus": {},
      "lookupkey": {
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "comments": "Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring, and comorbidities. Recommendation based upon data extrapolated from adults.",
      "population": "pediatrics",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C19": "Normal voriconazole metabolism"
      },
      "drugrecommendation": "Initiate therapy with recommended standard of care dosing",
      "classification": "Strong",
      "phenotypes": {
        "CYP2C19": "Normal Metabolizer"
      },
      "activityscore": {},
      "allelestatus": {},
      "lookupkey": {
        "CYP2C19": "Normal Metabolizer"
      },
      "comments": "Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring, and comorbidities.",
      "population": "adults",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C19": "Normal voriconazole metabolism"
      },
      "drugrecommendation": "Initiate therapy with recommended standard of care dosing",
      "classification": "Strong",
      "phenotypes": {
        "CYP2C19": "Normal Metabolizer"
      },
      "activityscore": {},
      "allelestatus": {},
      "lookupkey": {
        "CYP2C19": "Normal Metabolizer"
      },
      "comments": "Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring, and comorbidities.",
      "population": "pediatrics",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C19": "Higher dose-adjusted trough concentrations of voriconazole and may increase probability of adverse events"
      },
      "drugrecommendation": "Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include liposomal amphotericin B and posaconazole. In the event that voriconazole is considered to be the most appropriate agent, based on clinical advice, for a patient with poor metabolizer genotype, voriconazole should be administered at a preferably lower than standard dosage with careful therapeutic drug monitoring.",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2C19": "Poor Metabolizer"
      },
      "activityscore": {},
      "allelestatus": {},
      "lookupkey": {
        "CYP2C19": "Poor Metabolizer"
      },
      "comments": "Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring, and comorbidities. Recommendation based upon data extrapolated from adults.",
      "population": "pediatrics",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C19": "Higher dose-adjusted trough concentrations of voriconazole and may increase probability of adverse events"
      },
      "drugrecommendation": "Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole. In the event that voriconazole is considered to be the most appropriate agent, based on clinical advice, for a patient with poor metabolizer genotype, voriconazole should be administered at a preferably lower than standard dosage with careful therapeutic drug monitoring.",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2C19": "Poor Metabolizer"
      },
      "activityscore": {},
      "allelestatus": {},
      "lookupkey": {
        "CYP2C19": "Poor Metabolizer"
      },
      "comments": "Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring, and comorbidities.",
      "population": "adults",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C19": "In patients for whom a rapid metabolizer genotype (*1/*17) is identified, the probability of attainment of therapeutic concentrations is variable."
      },
      "drugrecommendation": "Initiate therapy with recommended standard of care dosing. Use therapeutic drug monitoring to titrate dose to therapeutic trough concentrations.",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2C19": "Rapid Metabolizer"
      },
      "activityscore": {},
      "allelestatus": {},
      "lookupkey": {
        "CYP2C19": "Rapid Metabolizer"
      },
      "comments": "Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring (TDM), and comorbidities. Achieving voriconazole therapeutic concentrations in the pediatric population with ultrarapid and rapid metabolizer phenotypes in a timely manner is difficult. As critical time may be lost in achieving therapeutic concentrations, an alternative antifungal agent is recommended in order that the child receives effective antifungal therapy as soon as possible. Meticulous TDM is critical for rapid metabolizers. There is insufficient evidence to distinguish a CYP2C19*1/*17 and *1/*1 pediatric patient due to large variability in trough concentrations.",
      "population": "pediatrics",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C19": "In patients for whom a rapid metabolizer genotype (*1/*17) is identified, the probability of attainment of therapeutic concentrations is modest with standard dosing"
      },
      "drugrecommendation": "Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole.",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2C19": "Rapid Metabolizer"
      },
      "activityscore": {},
      "allelestatus": {},
      "lookupkey": {
        "CYP2C19": "Rapid Metabolizer"
      },
      "comments": "Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring, and comorbidities.",
      "population": "adults",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C19": "In patients for whom an ultrarapid metabolizer genotype (*17/*17) is identified, the probability of attainment of therapeutic voriconazole concentrations is small with standard dosing"
      },
      "drugrecommendation": "Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole.",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "activityscore": {},
      "allelestatus": {},
      "lookupkey": {
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "comments": "Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring, and comorbidities. Recommendations based upon data extrapolated from patients with CYP2C19*1/*17 genotype.",
      "population": "adults",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C19": "In patients for whom an ultrarapid metabolizer genotype (*17/*17) is identified, the probability of attainment of therapeutic concentrations is small"
      },
      "drugrecommendation": "Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include liposomal amphotericin B and posaconazole.",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "activityscore": {},
      "allelestatus": {},
      "lookupkey": {
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "comments": "Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring, and comorbidities. Achieving voriconazole therapeutic concentrations in the pediatric population with ultrarapid and rapid metabolizer phenotypes in a timely manner is difficult. As critical time may be lost in achieving therapeutic concentrations, an alternative antifungal agent is recommended in order that the child receives effective antifungal therapy as soon as possible.",
      "population": "pediatrics",
      "genotypes": null
    }
  ],
  "genes": [
    "CYP2C19"
  ],
  "notesonusage": null,
  "cpicVersion": "v1.21.2",
  "source": "CPIC"
}